These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 29727332)

  • 41. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remnant gastric cancer: a neglected group with high potential for immunotherapy.
    Ramos MFKP; Pereira MA; de Castria TB; Ribeiro RRE; Cardili L; de Mello ES; Zilberstein B; Ribeiro-Júnior U; Cecconello I
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3373-3383. PubMed ID: 32671505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    BMC Cancer; 2019 Feb; 19(1):142. PubMed ID: 30755167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
    Ho HL; Chou TY; Yang SH; Jiang JK; Chen WS; Chao Y; Teng HW
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1785-1794. PubMed ID: 31129768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microsatellite Instability Analysis and Its Prognostic Value in Invasive Nonampullary Duodenal Adenocarcinoma.
    Yang G; Tanaka T; Kinugasa H; Kanzaki H; Chen MX; Ichimura K; Nakagawa M; Jin ZS; Zheng RY; Yoshino T
    Oncology; 2022; 100(5):290-302. PubMed ID: 35350032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.
    Pereira MA; Dias AR; Ramos MFKP; Cardili L; Moraes RDR; Zilberstein B; Nahas SC; Mello ES; Ribeiro U
    J Surg Oncol; 2022 Jul; 126(1):116-124. PubMed ID: 35689583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
    Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
    PeerJ; 2021; 9():e11481. PubMed ID: 34046266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
    Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
    Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM; Gong J; Klempner SJ; Chao J
    World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Randon G; Kook MC; An JY; Grabsch HI; Prisciandaro M; Nichetti F; Noh SH; Sohn TS; Kim S; Wotherspoon A; Morano F; Cunningham D; Lee J; Cheong JH; Smyth EC; Pietrantonio F
    Eur J Cancer; 2024 May; 203():114043. PubMed ID: 38598921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.